Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MHB018A in Active Moderate-to-Severe Thyroid Eye Disease
NCT06989918Phase 3Active, not recruiting
- Sponsor
- Minghui Pharmaceutical, Inc.
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Nanobodies (VHH), Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of MHB018A in thyroid eye disease (TED), sponsored by Minghui Pharmaceutical, Inc.. Started Jul 2025; status: active, not recruiting.
02
Drugs
MHB018A
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT06989918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06989918.